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Background: The management of using a mesh graft in the anterior compartment is reported to lead to
a higher rate of recurrent prolapse after anterior colporrhaphy than after mesh repair. Several ran-
domized controlled trials (RCTs) have shown no signiﬁcantly superior subjective cure rates or reop-
eration rates, despite better anatomical cure rates with synthetic mesh compared with traditional
anterior colporrhaphy for anterior compartment defects, however, the follow-up period in most RTCs
was only 1 year.
Objective: To evaluate the objective and subjective outcome in women with symptomatic advanced
pelvic organ prolapse (POP) who underwent sacrospinous ﬁxation (SSF) with anterior vaginal mesh
(AVM). We postulated that in the hands of well-trained surgeons, AVM plus SSF yields better long-term
success rates with a low rate of mesh-related complications. We studied the long-term postoperative
outcomes of SSF with AVM.
Study design: This was a retrospective study of 114 patients who underwent surgery for POP between
January 2006 and March 2010. Patient assessment at baseline and 3-year postoperative follow-up was
analyzed. SSF plus AVM was performed for apical and anterior compartment repair. Primary outcome
was objective cure (POP Quantiﬁcation Stage  1) and subjective cure deﬁned as a negative response to
Questions 2 and 3 on the POP Distress Inventory 6. Secondary outcomes were complications, symptoms
severity, and quality of life as measured using validated questionnaires.
Results: Postoperative data for 114 patients were analyzed. Median follow up was 59.6 months. All
patients completed a minimum of 3 years follow up. The objective cure rate was 100% for anterior and
apical compartments and 90.4% for posterior compartment. Regarding the individual compartment,
the cure rate was signiﬁcantly high (p < 0.001 for all compartments).
There were four cases (3.5%) of mesh exposure in which all patients were treated under local anesthetic
with excision of the exposed mesh without additional suturing of vaginal tissue at the outpatient ofﬁce.
Topical estrogen therapy was prescribed to facilitate re-epithelialization of vaginal wounds. There were
no cases of mesh erosion into the bladder or other organs, and no patient needed mesh removal due to
chronic pain or infection.
There was no recurrence in the anterior and apical compartment. Eleven patients (9.6%) had recurrence
of the posterior compartment during postoperative follow up.
There was a signiﬁcant improvements in all questionnaires with p < 0.001 for POP Distress Inventory 6,
Urogenital Distress Inventory, and Incontinence Impact Questionnaire, and p ¼ 0.001 for Prolapse/Uri-
nary Incontinence Sexual Function Questionnaire. There was no signiﬁcant difference for preoperative
and 1-year postoperative urodynamic diagnosis. There were seven cases of occult urodynamic stress
incontinence.
Conclusion: The Perigee System gave a favorable result in both anatomical and subjective success rates
with a low rate of mesh-related morbidities. The strength of the study reported here is its long-term
follow up of a relatively large number of patients and the use of validated questionnaires. Limitations
are that it is not a RCT; hence, selection and indication bias is unavoidable. The favorable outcome ande no conﬂicts of interest.
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Pelvic organ prolapse (POP) may occur in up to 50% of parous
women.1 The lifetime risk of undergoing surgery for POP in the
general female population aged  85 years has recently been re-
ported to be as high as 19e20%.2,3 This high likelihood of under-
going surgery for POP combined with the knowledge of anatomic
failure rates for native tissue repairs, that range between 30% and
70% for the anterior vaginal wall and approximately 20% for the
posterior vaginal wall, has led to the increased use of prosthetic
mesh in vaginal prolapse surgery with the main aim to reduce
anatomic failure rates and increase the durability of repairs.4e7 The
management of using a mesh graft in the anterior compartment is
supported by a recent Cochrane review1 which reported a higher
rate of recurrent prolapse after anterior colporrhaphy than after
mesh repair. Several randomized controlled trials (RCTs) showed no
signiﬁcantly superior subjective cure rates or reoperation rates
despite better anatomical cure rates with synthetic mesh compared
with traditional anterior colporrhaphy for anterior compartment
defects,8 however, the follow-up period in most of these RCTs was
only 1 year. Therefore the conclusion made by the Food and Drug
Administration based on these ﬁndings stated that there is no
conclusive evidence that using transvaginally placed mesh in POP
repair is an improvement over traditional POP repair without mesh
and that it may expose patients to greater risks.9Materials and methods
Medical records of 198 patients who underwent primary POP
surgery without concomitant anti-incontinence surgery performed
between January 2006 and March 2010 were retrospectively
reviewed. In total 114 patients who had transvaginal anterior mesh
(AVM) plus sacrospinous ﬁxation (SSF) were evaluated. Inclusion
criteria comprised patients with POP stages 3 and 4 who under-
went primary POP repair. Patients who needed concomitant anti-
incontinence surgery, who had previous POP repair, or who were
unﬁt for surgeries were excluded. All patients had preoperative
evaluations, including detailed medical history, physical examina-
tion, and pelvic examination. Vaginal examinations were donewith
patients in the semisupine lithotomy position. A split-speculum
technique was used to evaluate descent of the vaginal vault, ante-
rior and posterior vaginal walls, and uterine prolapse with
maximum Valsalva maneuver. Prolapse staging was recorded ac-
cording to the POP Quantiﬁcation (POP-Q) system.10
Investigations included urinalysis, 1-hour pad test, cough stress
test, and multichannel urodynamic evaluation. All patients were
required to complete a 72-hour voiding diary, the Incontinence
Impact Questionnaire (IIQ-7),11 the Urogenital Distress Inventory
(UDI-6),12 the POP Distress Inventory 6 (POPDI-6),13 and the Pro-
lapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-
12)14 at baseline and during follow up at 12months and 36months.
Validated Chinese versions were used for all questionnaires.15 All
conditions were deﬁned according to the standards of the Inter-
national Continence Society.10
Patients with poorly controlled medical conditions were opti-
mized before surgery. All patients were counseled on the surgicalprocedures and informed of the potential beneﬁts and possible
complications during and following surgery. Risk of mesh-related
complications, e.g., mesh erosion, chronic pelvic pain, dyspar-
eunia, infection, and the possibility of needing additional pro-
cedures for mesh removal or trimming in case of mesh
complications, were included in the counseling. Patients made an
informed decision as to whether to have AVM surgery or not.
Postmenopausal patients received preoperative and postoperative
topical estrogen treatment unless contraindicated.Operative procedure
All surgeries were performed by the senior author (T.S.L.), who is
experienced in native tissue pelvic reconstructive surgery and
trained in vaginal mesh insertion. Surgeries performed include
vaginal hysterectomy, anterior vaginal mesh procedure (Perigee
System; AMS, Minnetonka, MN, USA) and, if indicated, a posterior
colporrhaphy. Right unilateral SSF via a posterior approach, as
described by Miyazaki,16 was adopted for all patients. Details of the
surgical procedure for AVM (Perigee) were described
previously.17,18
Cystoscopy to evaluate the integrity of the lower urinary tract
was performed. All patients were given a prophylactic antibiotic of
500 mg cefazolin prior to surgery that continued every 6 hours
postsurgery for 1 day. A Foley catheter and a vaginal pack (gauze
soaked with povidone iodine) were placed for 72 hours. Catheter-
ization was stopped once the amount of postvoid residual was
consistently <20% of that from self-voiding. Patients with a residual
urine volume persistently >150 mL for >5 days were taught to use
clean intermittent self-catheterization.
Follow-up visits were scheduled at 1week,1month, 3months, 6
months, 1 year, and annually thereafter. The outcome measure was
the objective cure rate at 3 years' follow up, deﬁned as POP-Q 1 at
the anterior vaginal wall and all compartments. Patient feedback on
POPDI-6 with no or mild sensation of protruding abdominal organ
(Question 3) and no or mild heaviness (Question 2) were consid-
ered subjective success.19
Descriptive statistics were used for demographics and periop-
erative data. Paired-sample t test, and either Chi-square or Fisher
exact test were applied for comparison of pre- and postoperative
continuous and categorical data, respectively. A repeated measures
analysis of variance (ANOVA) was used to determine whether a
difference in continuous follow up existed between groups in order
to decrease the chance of type 1 error. A value of p < 0.05 was
considered statistically signiﬁcant for all comparisons. All statistical
methods used the commercial software SPSS, version 17 (SPSS,
Chicago, IL, USA). The institutional review board of Chang-Gung
Memorial Hospital approved the chart evaluation of this study.Results
Median follow up was 59.6 months. All patients completed a
minimum of 3 years follow up. Preoperative demographics are as
shown in Table 1. The objective cure rate was 100% for the anterior
and apical compartment and 90.4% for the posterior compartment
Table 1
Baseline patient characteristics.
Baseline characteristics n ¼ 114
Age (y) 64.1 ± 11.7
Body mass index (kg/m2) 25.6 ± 3.6
Parity, median (SD) 4.2 (1.8)
Postmenopausal 93 (81.6)
Concurrent surgery: VH 95 (83.3)
Data are presented as n (%) or mean ± SD unless otherwise stated.
SD ¼ standard deviation; VH ¼ vaginal total hysterectomy.
Table 4
Quality of life (QOL) scores preoperatively and at the 3-year postoperative follow up.
QOL
measurement
Patients with both baseline and 3-year follow-up score
Baseline 3-year follow up D Mean ± SD p
POPDI-6 15.1 ± 3.3 9.8 ± 2.0 5.2 ± 4.8 <0.001
PISQ-12 23.1 ± 5.0 29.0 ± 5.4 5.9 ± 8.4 0.001
UDI-6 14.1 ± 4.0 9.5 ± 2.9 4.6 ± 4.5 <0.001
IIQ-7 12.4 ± 5.4 8.3 ± 4.5 4.1 ± 3.5 <0.001
Data are presented as the mean ± standard deviation.
IIQ-7 ¼ Incontinence Impact Questionnaire (score 0e21); PISQ-12 ¼ Pelvic Organ
Prolapse/Urinary Incontinence Sexual Questionnaire (score 0e48); POPDI-6¼ Pelvic
Organ Prolapse Distress Inventory 6 (score 0e24); UDI-6 ¼ Urinary Distress In-
ventory (score 0e18).
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signiﬁcantly high (p < 0.001 for all compartments; Table 3).
There were four cases (3.5%) of mesh exposure inwhich all were
treated under local anesthetic with excision of the exposed mesh
without additional suturing of vaginal tissue at the outpatient of-
ﬁce. Topical estrogen therapy was prescribed to facilitate re-
epithelialization of vaginal wounds. There were no cases of mesh
erosion into the bladder or other organs, and no patient needed
mesh removal due to chronic pain or infection.
There was no recurrence in the anterior and apical compart-
ment; 11/114 (9.6%) patients had recurrence of the posterior
compartment during postoperative follow up. There was a signiﬁ-
cant improvement in all questionnaires with p < 0.001 for POPDI-6,
UDI-6, and IIQ-7 and p ¼ 0.001 for PISQ-12 (Table 4); however,
there were only 67 patients (58.7%) available for PISQ-12 analysis.
There was no signiﬁcant difference for preoperative and 1-year
postoperative urodynamic diagnosis. There were seven cases of
occult urodynamic stress incontinence.
Discussion
Demographics in this study showed themean agewas 64.1 years
and median parity was 4.2. Another large population study showed
that those who underwent vaginal mesh surgery (median 59 years,Table 2
Individual compartment cure rate preoperatively and at the 3-year postoperative
follow up.
Compartment Preop POP-Q > 1 Postop POP-Q > 1 p
Anterior 114 (100) 0 <0.001
Apical 114 (100) 0 <0.001
Posterior 114 (100) 11 (9.6) <0.001
Data are presented as n (%).
POP-Q ¼ Pelvic Organ Prolapse Quantiﬁcation system staging; Postop ¼ post-
operatively; Preop ¼ preoperatively.
Table 3
Pelvic Organ Prolapse Quantiﬁcation (POP-Q) staging preoperatively and at the
3-year postoperative follow up.
Compartment Staging Preop Postop
Anterior 1 0 114 (100)
n ¼ 114 2 5 (4.4) 0
3 61 (53.5) 0
4 48 (42.1) 0
Apical 1 0 114 (100)
n ¼ 114 2 2 (1.8) 0
3 71 (62.3) 0
4 41 (36.0) 0
Posterior 1 0 103 (90.4)
n ¼ 114 2 8 (7.0) 8 (7.0)
3 60 (25.6) 3 (2.6)
4 46 (40.4) 0
Data are presented as n (%).
Postop ¼ postoperatively; Preop ¼ preoperatively.interquartile range 52e67) were older than those who underwent
native tissue repair; (median 55 years, interquartile range 47e63;
p < 0.001).20 Age and sexual activity were the signiﬁcant inde-
pendent predictors of late mesh exposure in previous studies.21,22
The objective success rate was high: 90.4% for the posterior
compartment and 100% for both the anterior and apical compart-
ment. This is comparable with other studies; which reported an
overall success rate of 93.5% at 3 years in a retrospective study
utilizing Prolift T, Perigee, and Apogee23 and 97.1% across all 68
women who were followed up for at least 2 years.24 None of the
recurrence of posterior compartment in our study was reoperated
because most had no bothersome symptoms and were asymp-
tomatic. Despite that, they did not report a worsening of prolapse-
related symptoms (POPDI-6). The higher success rate of anterior
repair in our study is possibly because we combined anterior repair
with SSF. Ideal repair of the anterior compartment should include a
concomitant apical support procedure because the magnitude of
anterior vaginal wall prolapse is a combined function of impair-
ment of the pubovisceral muscle and the uterosacral and cardinal
ligaments (apical support).25,26 The vaginal apex is often involved
in large cystoceles; therefore, concomitant apical support is
necessary with anterior compartment repair.27 The signiﬁcant in-
dividual compartment cure rate in all compartments may be
explained by ensuring better support for anterior prolapse with the
use of synthetic mesh, with less burden being exerted on the apical
compartment, together with the performance of SSF leading to a
better cure rate and lower recurrence of vault prolapse.
Many previous studies suggested no difference between trans-
vaginal mesh and native tissue repair in term of subjective cure rate
and quality of life despite superior objective cure rates in mesh-
augmented repair.28e30 Our study showed a signiﬁcant improve-
ment of quality of life as shown by the improvement in POPDI-6,
PISQ-12, UDI-6, and IIQ-7. The improved postoperative UDI-6 and
IIQ-7 scores may imply that the Perigee procedure improves lower
urinary tract symptoms. The most frequently observed complica-
tion was de novo stress urinary incontinence deﬁned as the sub-
jective complaint of stress incontinence after surgery in previously
continent women, and this subject matter is currently being
analyzed in our ongoing study. Mesh-related vaginal erosion is one
of the major drawbacks of this type of surgery, with an average
incidence of 10%.31,32 Notably our mesh exposure rate was 3.5%,
which is comparable with the rate reported by Cao et al33 (3.6%),
but much lower than the average reported rate of approximately
10%.1,31 The low rate shown in our study is probably because we
excluded the ﬁrst 20 cases during the learning curve and patients
with previous prolapse surgery. Long et al23 suggested that vaginal
erosion is less likely to occur beyond the learning curve. In addition,
using the hydrodissection technique to ensure inclusion of the full
thickness of the vagina epithelium and endopelvic fascia, together
with not trimming redundant vaginal tissue was adopted in order
to minimize the risk of mesh exposure. Some authors suggested
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our ﬁndings did not support this association, as we only had 3.5%
mesh exposure despite 91.3% (95/114 patients, 83.3%) concomitant
vaginal hysterectomy. The other rare complication reported by
Long and Wu33 is the vaginal adhesion band following a trans-
vaginal mesh repair, which needs to be addressed as part of
counseling preoperatively.
Conclusion
Transobturator nonabsorbable AVM combined with SSF yielded
a favorable and sustainable result over 3 years in anatomical and
subjective success rates. The rate of mesh-related morbidities was
low and acceptable.
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